Fresh analysis reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Findings released in a major health publication demonstrates that while obese people often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these drugs need to be informed of the danger of fast weight regain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight in about 18 months.
Analyzing Approaches
The study, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
Researchers emphasize that individuals who shed pounds through dieting typically experience a more gradual creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Regain
Doctors propose the way of the jabs explains the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the likelihood of relapse, the therapy might need to be life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "emphasize the persistent nature of excess weight," similar to managing conditions like hypertension.
User Experiences
Individuals who have come off the medication report a intense resurgence of hunger.
"It felt as if something that goes on and you become starving," said one woman.
This difficulty is worsened if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Interest
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is higher among females than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent fix and long-term success hinges on integrated behavioural changes.
